Your session is about to expire
← Back to Search
Anti-VEGF Therapy for Retinal Vein Occlusion
Study Summary
This trial will test whether anti-vascular endothelial growth factor therapy can improve vision in patients with retinal vein occlusion and whether measuring the level of vascular endothelial growth factor can help predict when treatment will be needed.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 4 trial • 26 Patients • NCT03022292Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have blockage in the veins of both of your eyes.Your vision in the eye being studied is worse than 20/100.You had a heart attack, stroke, or heart-related chest pain in the past 6 weeks.You currently have severe eye problems caused by diabetes.You have had a surgery called vitrectomy in your study eye before.You currently have a specific type of age-related vision loss.You currently have a problem with your optic nerve that causes a specific type of pupil abnormality.You have received treatment for a specific eye condition called retinal vein occlusion in the eye being studied.You have a specific eye condition called Retinal Vein Occlusion with swelling in the center of the retina, confirmed by special eye tests.Your eyesight is between nearly perfect and very poor.
- Group 1: Aflibercept
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What objectives are being pursued by this clinical investigation?
"The primary purpose of this trial, evaluated over a period extending from the baseline to 52 weeks, is to measure changes in Vascular Endothelial Growth Factor (VEGF) levels in anterior chambers. Secondary objectives include monitoring any alterations in Best Corrected Visual Acuity (BCVA), analysing chemokine CXCL1/GRO alpha/KC/Cytokine-induced neutrophil chemoattractant (CINC-1) and CXCL2/GRO beta/MIPs /CINC3 by an ELISA multiplex, as well as tracking the number of intravitreal"
Is this research endeavor still accepting new participants?
"Affirmative. Evident from the information on clinicaltrials.gov, this medical experiment is actively recruiting participants whose profiles match its criteria. This trial was first published on October 6th 2021 and most recently updated on January 5th 2022; it requires 10 patients to be recruited at a single site."
What diseases or ailments does this therapy typically target?
"This medication is typically prescribed for wet age-related macular degeneration (wAMD); nevertheless, it can also benefit patients with other conditions such as diabetic macular edema (DME) and generalised retinal swelling."
What security measures are in place to ensure the safety of those receiving this treatment?
"The safety of this particular intervention is highly regarded, and as such it scored a 3 on our rating system. This reflects the fact that it is approved for use in Phase 4 trials."
How many subjects are included in the ongoing clinical trial?
"Affirmative. The info available on clinicaltrials.gov suggests that this medical experiment is actively looking for applicants as of now. This study was initially posted on October 6th 2021, and has since been modified most recently on January 5th 2022. 10 candidates are being sought from a single site in total."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger